Effects of perioperative oxygen concentration on oxidative stress in adult surgical patients: a systematic review

Oldman, AH

http://hdl.handle.net/10026.1/17398

10.1016/j.bja.2020.09.050
British Journal of Anaesthesia
Elsevier BV

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Title:
The effects of perioperative oxygen concentration on oxidative stress in adult surgical patients: a systematic review

Authors
Alex H Oldman¹,², Daniel S Martin³,⁴, Martin Feelisch¹,², Michael PW Grocott¹,²,⁵, Andrew F Cumpstey¹,².

Affiliations
1. Critical Care Research Group, Southampton National Institute of Health Research, Biomedical Research Centre, University Hospital Southampton, Southampton, SO16 6YD, UK.
2. Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK.
3. University of Plymouth, Peninsular Medical School, The John Bull Building, Research Way, Plymouth Science Park, Plymouth, PL6 8BU, UK
4. Intensive Care Unit, Royal Free Hospital, Pond Street, London, NW3 2QG, UK
5. Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA

Keywords: Oxidative stress, inflammation, hyperoxia, oxygen, perioperative care, surgery, anaesthesia.

Corresponding author's address:
Dr Andrew Cumpstey
Anaesthesia and Critical Care research group
Department of Anaesthesia, E Level
University Hospital Southampton
Tremona Road
Southampton
SO16 6YD

Tel. no. 023 8120 5308

E-mail address: a.cumpstey@soton.ac.uk
Abstract:

The fraction of inspired oxygen (FIO$_2$) administered during general anaesthesia varies widely despite international recommendations to administer FIO$_2$=0.8 to all anaesthetised patients to reduce surgical site infections (SSIs). Anaesthetists remain concerned that high FIO$_2$ administration intraoperatively may increase harm, through increased oxidative damage and inflammation, resulting in more complications and worse outcomes. In previous systematic reviews associations between FIO$_2$ and SSIs have been inconsistent, but none have previously examined whether lower FIO$_2$ administration reduces perioperative oxidative stress.

Methods

EMBASE, MEDLINE, and Cochrane databases were searched from inception to 9$^{th}$ March 2020 for randomised controlled trials (RCTs) comparing higher with lower perioperative FIO$_2$ and quantifying oxidative stress in adults undergoing non-cardiac surgery. Candidate studies were independently screened by two reviewers and references hand-searched. Methodological quality was assessed using the Cochrane Collaboration Risk of Bias tool.

Results

From 19,438 initial results, seven trials (n=422) were included. Four studies reported markers of oxidative stress during caesarean section (n=328) and three reported oxidative stress during elective colon surgery (n=94). Risk of bias was low (4 studies) to moderate (3 studies). Pooled results suggested high FIO$_2$ was associated with greater malondialdehyde, protein-carbonyl concentrations and reduced xanthine oxidase concentrations, together with reduced antioxidant markers such as superoxide dismutase and total sulphhydryl levels although total antioxidant status was unchanged.
Conclusion

Higher FIO₂ may be associated with elevated oxidative stress during surgery. However, limited studies have specifically reported biomarkers of oxidation. Given the current clinical controversy concerning perioperative oxygen therapy, further research is urgently needed in this area.
Introduction

In 2016, the World Health Organization (WHO) recommended administering a fractional inspired oxygen concentration (FIO₂) of 0.8 to all intubated patients undergoing surgery to reduce surgical site infections (SSIs).¹ ² This was based on a meta-analysis of 15 trials performed by the WHO guideline development group (GDG),³ and remains controversial amongst anaesthetists.⁴–⁶ Notably, the findings of the largest trial available at the time (the PROXI study, n=1378,⁷) were deemed ‘biologically implausible’ by the GDG for reasons that remain obscure.² Post-hoc analyses from PROXI suggested higher intraoperative FIO₂ could be associated with higher long-term mortality in patients with cardiac disease and/or cancer.⁸ ⁹ A better understanding of the mechanisms underlying such outcome differences is essential to resolve this debate.

Systemic detrimental effects of oxygen are often thought to be mediated through ‘oxidative stress’ - an imbalance between the production of highly reactive by-products of metabolism (reactive oxygen species, ROS) and endogenous antioxidant defence mechanisms, also affecting local and systemic redox status.¹⁰–¹² ROS are largely formed during mitochondrial oxidative phosphorylation, or within neutrophil/macrophages and non-phagocytic cells.¹³–¹⁵ ROS can irreversibly damage lipids, proteins and DNA; triggering cell death through apoptosis or necrosis.¹³ ¹⁴ Oxidative stress can be beneficial (e.g. in phagocytosis) but can also lead to tissue damage and organ failure.¹⁶ ¹⁷

Direct detection of ROS remains challenging due to their short half-life. Markers of oxidation and antioxidant status are therefore used as indirect measures of ROS activity. Common markers of oxidation include lipid peroxides (e.g. malondialdehyde (MDA), F₂-isoprostanes and organic hydroperoxides (OHP)), which indicate levels of cellular lipid oxidation.¹⁸ ¹⁹
Similarly, protein carbonyl moieties (PCO) reflect levels of cellular protein oxidation.\textsuperscript{20} Xanthine oxidase (XO), a ROS generating enzyme, has also been used to assess ischaemic/reperfusion injury perioperatively; with tissue damage thought to be mediated by ADP catabolism, acidosis, subsequent XO production and neutrophil mediation.\textsuperscript{21–23}

Well-studied antioxidant enzymes include superoxide dismutase (SOD), glutathione peroxidase and catalase. Thiols (protein or non-protein compounds with free sulphhydryl groups) are also major targets of ROS-induced oxidation and common markers of extracellular (e.g. plasma) redox status, whilst the reduced to oxidized glutathione (GSG/GSSG) ratio is a common intracellular marker.\textsuperscript{24} Total antioxidant status (TAS) is a popular colorimetric assay used to compare overall levels of ‘antioxidant reserve capacity’ across different clinical samples.\textsuperscript{25,26}

Oxidative stress, fundamental to the inflammatory surgical stress response,\textsuperscript{16,27,28} is associated with more post-operative complications and worse post-operative outcomes.\textsuperscript{28–31} However, whether administering lower FIO\textsubscript{2}s intraoperatively reduces the magnitude of perioperative oxidative stress has not previously been determined.

**Methods**

This review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA),\textsuperscript{32} and was prospectively registered online at International Prospective Register of Systematic Reviews (PROSPERO, ID: CRD42017078995).

**Selection criteria**
Randomised controlled trials (RCTs), published in English, in adult (aged 18 years or more) patients undergoing any non-cardiac procedure in an operating theatre under general anaesthesia and not requiring one lung ventilation, neurosurgery or hyperbaric oxygen therapy were eligible. All included studies reported biochemical levels of oxidative stress (as agreed by all authors) in response to administration of either a high or low intraoperative FIO₂ (>0.6 vs <0.4, or ≥ 20% difference between interventional groups).

Search Strategy

EMBASE, MEDLINE, and Cochrane databases were searched from inception until 9th March 2020 for keywords relating to ROS, oxidative stress, oxygen, hyperoxia, anaesthesia and surgery. Full search strategies are detailed in Appendix A. Two authors (AHO & AFC) independently identified potentially eligible studies by screening all titles and abstracts using Rayyan (systematic review web application,33). Any disagreements were resolved by discussion with all other authors. Full texts of potentially eligible studies were obtained and reviewed by two authors (AHO & AFC). Review by other authors was available if consensus could not be reached, but not necessary. Included articles’ references were then hand-searched for completeness.

Data Extraction & assessment of methodological quality

Data was extracted, placed in an analysis table and independently cross checked by two authors (AHO & AFC). One author (AHO) used the Cochrane Collaboration Tool to assess Risk of Bias (CCRB) to assess methodological quality. Studies were scored as high, low or unclear risk in each of the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, complete outcome
data, selective reporting and other biases. Due to the high level of heterogeneity in the small number of results, a meta-analysis was not performed.

**Results**

The initial search located 19,438 results, of which 984 were duplicates. 124 were deemed potentially eligible following title and abstract review but 116 were excluded on reviewing the full texts, leaving 8 eligible studies (see figure 1). The most common reasons for exclusion were only reporting clinical outcomes and not specifically reporting on biochemical measures. One article was subsequently excluded from the analysis due to missing data despite attempts to contact the authors.\(^3^4\) Data from 422 patients in 7 studies were included in the final analysis.

**Characteristics of included studies**

From the available data, mean age was 38 (SD 13.9) years and weight 66.9 (SD 3.1) Kg. Of the 6 trials reporting participants’ sex (n = 392 total), only 47 (12%) participants were male. All 7 RCTs included in the analysis reported different biomarkers of oxidative stress in surgical patients (see table 1).\(^3^5\)–\(^4^1\) Four studies (three of which were from the same group) reported oxidative stress in maternal and fetal blood samples collected during either elective or emergency caesarean section.\(^3^7\)–\(^3^9\)\(^4^1\) One trial reported markers of oxidative stress in serum and bronchoalveolar lavage samples collected from 40 patients undergoing a hemicolecetomy procedure under general anaesthesia,\(^4^0\) and the final two studies (both from the same group) studied both mucosal and arterial levels of MDA intraoperatively and postoperatively during colon surgery.\(^3^5\)\(^3^6\)
Risk of bias in included studies

Of the seven studies analysed, four were deemed to have low risk of bias across all domains, and three articles were deemed to have a moderate risk of bias due to no reporting on blinding and patient group allocation concealment. A risk bias summary grid depicting these results is shown in figure 2. Combined results are listed in tables 1 and 2.

Markers of Oxidation

MDA was the most commonly reported biomarker of oxidative stress, reported in 5 of the 7 studies. Two studies demonstrated significant increases in MDA with higher FIO₂ in maternal & umbilical serum, and bronchial lavage. Two other studies (from the same group) reported significantly lower mucosal and postoperative arterial MDA concentrations with an FIO₂ of 0.8, and neither maternal nor umbilical MDA concentrations changed in the remaining study.

Three separate studies (from the same group) reported maternal and umbilical isoprostane concentrations. Although the earliest of these reported significant increases in the higher FIO₂ (=0.6) group, no significant differences were demonstrated in the latter two studies.

High FIO₂ was also associated with higher fetal organic hydroperoxide (OHP) concentrations, lower bronchial PCO concentrations and lower mucosal XO concentrations in three separate studies.

Antioxidant and cellular redox status
No differences in oxidised and reduced glutathione were demonstrated, either intraoperatively (1 hour after induction) or 6 hours after surgery, in two separate studies (both FIO₂ 0.3 vs 0.8) from the same group. \textsuperscript{35} \textsuperscript{36}  

Only two RCTs reported on other markers of antioxidant status (see Table 2). Koksal \textit{et al.} reported significant decreases in arterial and BAL SOD and PSH, and also BAL NPSH, with lower FIO₂ (0.4 vs 0.8) in 40 patients having colorectal surgery,\textsuperscript{40} and Ahuja \textit{et al.} reported no changes in TAS between control (FIO₂ 0.21) and intervention (FIO₂ 0.5) and in either maternal arterial, fetal arterial or fetal venous blood during elective and emergency Caesarean section.\textsuperscript{41} 

\textbf{Discussion} 

Evidence from this systematic review suggests that higher intraoperative FIO₂ could be associated with increased perioperative oxidative stress. Evidence from 138 patients across four studies demonstrated increased biomarkers of oxidative stress in serum and alveolar samples collected from patients receiving high FIO₂.\textsuperscript{35–37} \textsuperscript{40} However, the number and size of all of these studies was small and considerable uncertainty remains about which redox pathways might be most affected by intraoperative oxygen administration. We believe this to be the first systematic review reporting oxidative stress in response to different FIO₂s during surgery, and our findings show few (exclusively small single-centre) trials have explored this during surgery to date. This is surprising given that in many other clinical settings adverse outcomes have been associated with both excess oxygen administration,\textsuperscript{42–50} and also different markers of redox activity.\textsuperscript{51–60}
Significant increases in MDA (used as a serum and tissue marker in 4 of the 7 included trials) were observed across neonatal cord blood, arterial, bronchial and colon mucosal samples given high FIO\textsubscript{2}. MDA and isoprostane represent final oxidation products of polyunsaturated fatty acids, suggesting FIO\textsubscript{2} might affect lipid membrane composition during surgery. Interestingly, serum MDA concentrations showed no change between different FIO\textsubscript{2} levels (0.4 and 0.8) in one study, but did increase within BAL and arterial samples, suggesting most oxidative stress may occur within the pulmonary vasculature.\textsuperscript{40} ROS induced hypoxia induced acute lung injury (HALI), a state of increased permeability of the alveolar/vascular interface and endothelial disruption (also mediated by interleukins, cytokines and chemokines) is well described,\textsuperscript{61} and direct disruption of type 2 epithelial cells by oxidative and inflammatory mediators promotes cellular apoptotic and necrotic pathways.\textsuperscript{62} In contrast during elective C-section, isoprostan and MDA concentrations in both maternal and umbilical serum increased up to 2-fold with FIO\textsubscript{2} 0.6,\textsuperscript{37} supporting other research showing that redox mediators can cross the placenta.\textsuperscript{63} However, MDA concentrations did not change in a second study where mothers received FIO\textsubscript{2} of 0.21 or 0.5 during both elective and emergency operations,\textsuperscript{41} possibly due to either the lower FIO\textsubscript{2} or shorter duration (<10 minutes vs >52 minutes) of oxygen exposure. Oxidative stress has been implicated in multiple obstetric complications including preterm labour, maternal vascular disease and miscarriage, with ROS formation causing lipid peroxidation, membrane disruption of placental tissue, and dysregulation of fetal growth and development.\textsuperscript{64–66} It is worth noting that all participants in Khaw et al.’s trials received spinal (regional) anaesthesia alone, so these results may not be directly comparable to patients undergoing endotracheal intubation and general anaesthesia.
Only one trial reported xanthine oxidase (XO) expression, an enzyme family known to directly generate ROS,\textsuperscript{36} suggesting that inspiring high F\textsubscript{IO\textsubscript{2}} may attenuate XO activity at a tissue level and reduce ROS production. Given that urate, a common product of XO activity, is also one of the main constituents of many assays used to measure total antioxidant capacity,\textsuperscript{67} other measures of antioxidant activity might also be expected to respond similarly to hyperoxia. Lack of consistency as to how antioxidant status is reported makes direct comparison challenging - two studies only reported oxidised and reduced glutathione concentrations,\textsuperscript{35,36} whilst two other trials reported alternative markers of activity including SOD, NPSH, PSH and TAS.\textsuperscript{40,41} In one of these latter trials, SOD expression and both NPSH and PSH concentrations were significantly reduced with high F\textsubscript{IO\textsubscript{2}} administration,\textsuperscript{40} suggesting that lower concentrations of oxygen may stimulate a greater antioxidant response or that excess oxygen might ‘consume’ cellular antioxidant capacity. In contrast, the other trial reported no significant differences in TAS,\textsuperscript{41} suggesting oxidative stress was not associated with reciprocal anti-oxidation responses in these procedures performed under regional (as opposed to general) anaesthesia.

Our analysis is limited by the quantity and quality of research conducted in this area. Of the seven studies identified in the current systematic review, only four studies were deemed to have low risk of reporting bias in all domains (figure 3). Furthermore, a high proportion of participants were young females as four of the seven included studies (more than half of all of the included trials) only recruited participants having Caesarean section procedures. It is not known how perioperative redox changes might differ between obstetric and non-obstetric surgery, but redox markers are known to vary with age, sex, body habitus and pregnancy.\textsuperscript{68} Another limitation that has hampered progress in this field is the lack of a
conceptual framework for what oxidative stress actually means in vivo. Many different readouts have been proposed and are currently being used as indicators of the involvement of ROS in clinical settings without a clear understanding what any of these analytes actually ‘mark’ or how these different ‘readouts of cellular activity’ may interact with each other. 

Taken together, our findings evidence a striking lack of high-quality research exploring the cellular consequences of perioperative oxygen administration in patients undergoing major surgery. Historically, perioperative oxygen research has focussed on the effects of hyperoxia on SSI rates as well as nausea and vomiting. However, larger trials (such as PROXI) and meta-analyses demonstrate that the presumed association between hyper-oxygenation and reduction in SSI rates is uncertain, and there remains strong evidence to suggest that ROS formation increases perioperative tissue inflammation. Understanding whether oxygen causes shifts in the production of ROS and antioxidants has considerable clinical implications and more work is urgently needed to explore these mechanisms that underlie so many current practices in perioperative medicine.

**Detail of author contributions**

Study conception and design: All authors

Data acquisition: AHO and AFC

Data interpretation: All authors

Manuscript drafting: AHO and AFC

Manuscript revision, editing and approval: All authors
Acknowledgements

The authors would like to acknowledge the significant contribution of Ms Paula Sands of the Healthcare sciences laboratory at the University of Southampton, UK for her assistance in developing and running literature searches for this project over a period of 48 months.

Declaration of interests

DSM has received honoraria for speaking and consultancy work from Siemens Healthineers and Edwards Lifesciences, and is a director of Oxygen Control Systems Ltd. MPWG serves on the medical advisory board of Sphere Medical Ltd. and is a director of Oxygen Control Systems Ltd. He has received honoraria for speaking for and/or travel expenses from BOC Medical (Linde Group), Edwards Lifesciences and Cortex GmbH. MPWG leads the Xtreme Everest Oxygen Research Consortium and the Fit-4-Surgery research collaboration. Some of this work was undertaken at University Southampton NHS Foundation Trust–University of Southampton NIHR Biomedical Research Centre. MPWG serves as the UK NIHR CRN national specialty group lead for Anaesthesia Perioperative Medicine and Pain and is an elected council member of the Royal College of Anaesthetists and president of the Critical Care Medicine Section of the Royal Society of Medicine. All other authors have no pertinent conflicts of interests to declare.
Funding

AHO is in receipt of the NIHRs Young Researchers Career Development Fund through the NIHR Southampton Biomedical Research Centre.

AFC has received funding through the NIHR as an Academic Clinical Fellow and from Southampton NIHR Biomedical Research Centre as a Clinical Research Fellow.

References

1. Allegranzi B, Zayed B, Bischoff P, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. *The Lancet Infectious Diseases* 2016; 16: e288–303

2. World Health Organization. Global guidelines for the prevention of surgical site infection. [Internet]. 1st ed. 2016 [cited 2020 Jun 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK401132/

3. World Health Organisation. Global guidelines for the prevention of surgical site infection web appendix13.pdf [Internet]. [cited 2020 Jun 27]. Available from: https://www.who.int/gpsc/appendix13.pdf?ua=1

4. Myles PS, Kurz A. Supplemental oxygen and surgical site infection: getting to the truth. *Br J Anaesth* 2017; 119: 13–5

5. Oldman AH, Cumpstey AF, Martin DS, Grocott MPW. Data integrity issues: catalyst for a more robust approach to research on perioperative oxygen therapy? *Perioperative Medicine* 2019; 8:

6. Munshi L, Ferguson ND. Evolving Issues in Oxygen Therapy in Acute Care Medicine. *JAMA* 2020; 323: 607–8

7. Meyhoff CS, Wetterslev J, Jorgensen LN, et al. Effect of High Perioperative Oxygen Fraction on Surgical Site Infection and Pulmonary Complications After Abdominal Surgery: The PROXI Randomized Clinical Trial. *JAMA* 2009; 302: 1543–50

8. Fonnes S, Gøgenur I, Søndergaard ES, et al. Perioperative hyperoxia — Long-term impact on cardiovascular complications after abdominal surgery, a post hoc analysis of the PROXI trial. *International Journal of Cardiology* 2016; 215: 238–43

9. Meyhoff CS, Jorgensen LN, Wetterslev J, Christensen KB, Rasmussen LS, PROXI Trial Group. Increased long-term mortality after a high perioperative inspiratory oxygen fraction during abdominal surgery: follow-up of a randomized clinical trial. *Anesth Analg* 2012; 115: 849–54
10. Jamieson D, Chance B, Cadenas E, Boveris A. The Relation of Free Radical Production to Hyperoxia. *Annual Review of Physiology* 1986; **48**: 703–19

11. Halliwell B. Reactive Species and Antioxidants. Redox Biology Is a Fundamental Theme of Aerobic Life. *Plant Physiology* American Society of Plant Biologists; 2006; **141**: 312–22

12. Sies H, Berndt C, Jones DP. Oxidative Stress. *Annual Review of Biochemistry* 2017; **86**: 715–48

13. Auten RL, Davis JM. Oxygen toxicity and reactive oxygen species: the devil is in the details. *Pediatr Res* 2009; **66**: 121–7

14. Helmerhorst HJF, Schultz MJ, van der Voort PHJ, de Jonge E, van Westerloo DJ. Bench-to-bedside review: the effects of hyperoxia during critical illness. *Crit Care* [Internet] 2015 [cited 2016 Sep 6]; **19** Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538738/

15. Panday A, Sahoo MK, Osorio D, Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. *Cell Mol Immunol* 2015; **12**: 5–23

16. Cumpstey A, Feelisch M. Free Radicals in Inflammation. In: Cavaillon J-M, Singer M, editors. *Inflammation: From Molecular and Cellular Mechanisms to the Clinic, 4 volume set* Wiley; 2017. p. 695–726

17. Chen Y, Zhou Z, Min W. Mitochondria, Oxidative Stress and Innate Immunity. *Front Physiol* [Internet] 2018 [cited 2020 May 14]; **9** Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200916/

18. Ho E, Karimi KG, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. *Redox Biol* 2013; **1**: 483–91

19. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. *Clin Chem* 1995; **41**: 1819–28

20. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. *Clin Chim Acta* 2003; **329**: 23–38

21. Chung HY, Baek BS, Song SH, et al. Xanthine dehydrogenase/xanthine oxidase and oxidative stress. *Age (Omaha)* 1997; **20**: 127–40

22. Anup R, Aparna V, Pulimood A, Balasubramanian KA. Surgical stress and the small intestine: role of oxygen free radicals. *Surgery* 1999; **125**: 560–9

23. Gabriel EA, Mazza CA, Mello MAJ de. Use of Antioxidants in Cardiovascular Surgery. *International Journal of Nutrology* Thieme Revinter Publicações Ltda; 2018; **11**: 80–6

24. Harris C, Hansen JM. Oxidative stress, thiols, and redox profiles. *Methods Mol Biol* 2012; **889**: 325–46

25. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. *Clin Biochem* 2004; **37**: 277–85

26. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. *Meth Enzymol* 1994; **234**: 279–93
27. López-Armada MJ, Riveiro-Naveira RR, Vaamonde-García C, Valcárcel-Ares MN. Mitochondrial dysfunction and the inflammatory response. *Mitochondrion* 2013; **13**: 106–18

28. Kücükakin B, Gögenur I, Reiter RJ, Rosenberg J. Oxidative stress in relation to surgery: is there a role for the antioxidant melatonin? *J Surg Res* 2009; **152**: 338–47

29. Zakkar M, Ascione R, James AF, Angelini GD, Suleiman MS. Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery. *Pharmacology & Therapeutics* 2015; **154**: 13–20

30. Senoner T, Schindler S, Stättner S, Öfner D, Troppmair J, Primavesi F. Associations of Oxidative Stress and Postoperative Outcome in Liver Surgery with an Outlook to Future Potential Therapeutic Options. *Oxidative medicine and cellular longevity* 2019;

31. Araki O, Matsumura Y, Inoue T, et al. Association of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection. *AnnThoracCardiovascSurg* 2018; **24**: 13–8

32. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* [Internet] 2009 [cited 2020 Jun 26]; 6 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707599/

33. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Syst Rev* [Internet] 2016 [cited 2020 Jun 26]; 5 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139140/

34. Singh V, Hooda S, Dahiya K, Sharma R. Effect of Different Inspired Oxygen Concentrations During Caesarean Section Under Spinal Anaesthesia on Maternal and Foetal Oxygenation and Lipid Peroxidation. *Bombay Hospital Journal* 2006; **4**: 561–6

35. García de la Asunción J, Belda FJ, Greif R, Barber G, Viña J, Sastre J. Inspired supplemental oxygen reduces markers of oxidative stress during elective colon surgery. *Br J Surg* 2007; **94**: 475–7

36. García-de-la-Asunción J, Barber G, Rus D, et al. Hyperoxia during colon surgery is associated with a reduction of xanthine oxidase activity and oxidative stress in colonic mucosa. *Redox Rep* 2013; **16**: 121–8

37. Khaw KS, Wang CC, Ngan Kee WD, Pang CP, Rogers MS. Effects of high inspired oxygen fraction during elective caesarean section under spinal anaesthesia on maternal and fetal oxygenation and lipid peroxidation. *Br J Anaesth* 2002; **88**: 18–23

38. Khaw KS, Wang CC, Kee WDN, et al. Supplementary oxygen for emergency Caesarean section under regional anaesthesia† ‡. *British Journal of Anaesthesia* Elsevier; 2009; **102**: 90–6

39. Khaw KS, Ngan Kee WD, Chu CY, et al. Effects of different inspired oxygen fractions on lipid peroxidation during general anaesthesia for elective Caesarean section. *Br J Anaesth* 2010; **105**: 355–60

40. Koksal GM, Dikmen Y, Erbabacan E, et al. Hypoxic oxidative stress during abdominal surgery: a randomized trial. *J Anesth* 2016; **30**: 610–9

41. Ahuja V, Gombar S, Jaswal S, et al. Effect of maternal oxygen inhalation on foetal free radical activity: a prospective, randomized trial. *Acta Anaesthesiologica Scandinavica* 2018; **62**: 26–37
42. Chu DK, Kim LH-Y, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *The Lancet* 2018; **391**: 1693–705

43. de Jonge E, Peelen L, Keijzers PJ, et al. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. *Crit Care* 2008; **12**: R156

44. Damiani E, Adrario E, Girardis M, et al. Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. *Critical Care* 2014; **18**: 711

45. Cabello JB, Burls A, Empananza JJ, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. *Cochrane Database of Systematic Reviews* [Internet] John Wiley & Sons, Ltd; 2013 [cited 2016 Jul 5]. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007160.pub3/abstract

46. Kilgannon J, Jones AE, Shapiro NI, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA* 2010; **303**: 2165–71

47. Rincon F, Kang J, Maltenfort M, et al. Association between hyperoxia and mortality after stroke: a multicenter cohort study. *Crit Care Med* 2014; **42**: 387–96

48. Davis DP, Meade W, Sise MJ, et al. Both Hypoxemia and Extreme Hyperoxemia May Be Detrimental in Patients with Severe Traumatic Brain Injury. *Journal of Neurotrauma* 2009; **26**: 2217–23

49. Brenner M, Stein D, Hu P, Kufera J, Wooford M, Scalea T. Association between early hyperoxia and worse outcomes after traumatic brain injury. *Arch Surg* 2012; **147**: 1042–6

50. Martin DSBs, Grocott MPWM. Oxygen Therapy in Critical Illness: Precise Control of Arterial Oxygenation and Permissive Hypoxemia*. *Critical Care Medicine* 2013; **41**: 423–32

51. Frenay A-RS, de Borst MH, Bachtler M, et al. Serum free sulfhydryl status is associated with patient and graft survival in renal transplant recipients. *Free Radic Biol Med* 2016; **99**: 345–51

52. Koning AM, Meijers WC, Pasch A, et al. Serum free thiols in chronic heart failure. *Pharmacol Res* 2016; **111**: 452–8

53. Banne AF, Amiri A, Pero RW. Reduced level of serum thiols in patients with a diagnosis of active disease. *J Anti Aging Med* 2003; **6**: 327–34

54. Kundi H, Ates I, Kiziltunc E, et al. A novel oxidative stress marker in acute myocardial infarction; thiol/disulphide homeostasis. *Am J Emerg Med* 2015; **33**: 1567–71

55. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative Stress Markers Are Associated with Persistent Atrial Fibrillation. *Clin Chem* 2007; **53**: 1652–7

56. Kopčinović LM, Domijan A-M, Posavac K, Čepelak I, Grubišić TŽ, Rumora L. Systemic redox imbalance in stable chronic obstructive pulmonary disease. *Biomarkers* 2016; **21**: 692–8

57. Stephenson ST, Brown LAS, Helms MN, et al. Cysteine oxidation impairs systemic glucocorticoid responsiveness in children with difficult-to-treat asthma. *Journal of Allergy and Clinical Immunology* Elsevier; 2015; **136**: 454-461.e9
58. Go Y-M, Jones DP. Cysteine/cystine redox signaling in cardiovascular disease. *Free Radic Biol Med* 2011; **50**: 495–509

59. Liou G-Y, Storz P. Reactive oxygen species in cancer. *Free Radic Res* 2010; **44**: 479–96

60. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. *Biochem J* 1996; **313**: 17–29

61. Bhandari V. Molecular mechanisms of hyperoxia-induced acute lung injury. *Front Biosci* 2008; **13**: 6653–61

62. Yee M, Vitiello PF, Roper JM, et al. Type II epithelial cells are critical target for hyperoxia-mediated impairment of postnatal lung development. *Am J Physiol Lung Cell Mol Physiol* 2006; **291**: L1101-1111

63. Argüelles S, Machado MJ, Ayala A, Machado A, Hervías B. Correlation between circulating biomarkers of oxidative stress of maternal and umbilical cord blood at birth. *Free Radical Research* Taylor & Francis; 2006; **40**: 565–70

64. Duhig K, Chappell LC, Shennan AH. Oxidative stress in pregnancy and reproduction. *Obstet Med* 2016; **9**: 113–6

65. Vural P, Akgül C, Yildirim A, Canbaz M. Antioxidant defence in recurrent abortion. *Clin Chim Acta* 2000; **295**: 169–77

66. Wang Y, Walsh SW. Placental mitochondria as a source of oxidative stress in pre-eclampsia. *Placenta* 1998; **19**: 581–6

67. Ryan M, Grayson L, Clarke DJ. The total antioxidant capacity of human serum measured using enhanced chemiluminescence is almost completely accounted for by urate. *Ann Clin Biochem* 1997; **34 (Pt 6)**: 688–9

68. Stevens JL, Feelisch M, Martin DS. Perioperative Oxidative Stress: The Unseen Enemy. *Anesth Analg* 2019; **129**: 1749–60

69. Cortese-Krott MM, Koning A, Kuhnle GGC, et al. The Reactive Species Interactome: Evolutionary Emergence, Biological Significance, and Opportunities for Redox Metabolomics and Personalized Medicine. *Antioxid Redox Signal* 2017; **27**: 684–712

70. Greif R, Açıka O, Horn E-P, Kurz A, Sessler DI. Supplemental Perioperative Oxygen to Reduce the Incidence of Surgical-Wound Infection. *New England Journal of Medicine* 2000; **342**: 161–7

71. Belda FJ, Aguiler L, García de la Asunción J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. *JAMA* 2005; **294**: 2035–42

72. Myles PS, Leslie K, Chan MTV, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. *Anesthesiology* 2007; **107**: 221–31

73. Jonge S de, Egger M, Latif A, et al. Effectiveness of 80% vs 30–35% fraction of inspired oxygen in patients undergoing surgery: an updated systematic review and meta-analysis. *British Journal of Anaesthesia* Elsevier; 2019; **122**: 325–34
Fig. 1 Consort diagram

19,438 initial results
MEDLINE, EMBASE, Cochrane

984 duplicates excluded

18,454 titles and abstracts read

18,330 excluded through initial title and abstract screening

124 full texts accessed

116 excluded through full text review:
Only clinical outcomes reported (no markers of redox activity):
Surgical Site infection (n=30)
Inflammation (n=2)
Pulmonary function (n=30)
Post-op nausea and vomiting (n=16)
Maternal and fetal physiology (n=23)
Cardiac function (n=8)
Surgical complications (n=3)
Cerebral blood flow (n=2)
Haematological counts (n=2)

8 RCTs included for methodological quality assessment

Excluded due to lack of data (n=1)

7 RCTs fully analysed (patient n=422)
Fig 2. Bias grid

|                  | Khaw et al. 2002 | Garcia de la Asuncion et al. 2007 | Khaw et al. 2008 | Khaw et al. 2010 | Garcia de la Asuncion et al. 2013 | Koksal et al. 2016 | Ahuja et al. 2018 |
|------------------|------------------|----------------------------------|------------------|------------------|----------------------------------|-------------------|------------------|
| Random sequence generation | 🟢      | ?                               | 🟢               | 🟢               | 🟢                               | 🟢                 | 🟢               |
| Allocation concealment (selection bias) | 🟢      | ?                               | 🟢               | 🟢               | 🟢                               | 🟢                 | 🟢               |
| Blinding of participants and personnel (performance bias) | 🟢      | ?                               | 🟢               | 🟢               | 🟢                               | 🟢                 | 🟢               |
| Blinding of outcome assessment (detection bias) | ?       | ?                               | 🟢               | 🟢               | ?                               | 🟢                 | 🟢               |
| Complete outcome data (attrition bias) | 🟢      | 🟢                               | 🟢               | 🟢               | 🟢                               | 🟢                 | 🟢               |
| Selective reporting (reporting bias) | 🟢      | 🟢                               | 🟢               | 🟢               | 🟢                               | 🟢                 | 🟢               |
| No other bias    | 🟢      | ?                               | 🟢               | 🟢               | 🟢                               | 🟢                 | 🟢               |
### Tables

**Table 1.** Combined results of RCTs reporting on markers of oxidative stress in arterial blood, fetal blood, and bronchial lavage samples. *p<0.05 **p<0.01. EL C/S elective cesarean section; EM C/S: emergency cesarean section.

| Author          | Patient no. | Control vs. Intervention (FIO₂) | Sample (units)                        | Isoprostane | Organic Hydroperoxides | Malondialdehyde, MDA | Protein carbonyl, PCO | Xanthine Oxidase, XO |
|-----------------|-------------|---------------------------------|--------------------------------------|-------------|------------------------|-----------------------|-----------------------|----------------------|
| Khaw et al. 2002 | 44          | 0.21 vs. 0.6                     | Maternal arterial (µmol L⁻¹)          | 121.8 vs. 200.6** | 0.14 vs. 0.14          | 0.89 vs. 1.2**         | -                     | -                    |
|                 |             |                                  | Umbilical venous (µmol L⁻¹)            | 135.3 vs 403.0** | 0.15 vs. 0.5*           | 0.47 vs. 0.78*         | -                     | -                    |
|                 |             |                                  | Umbilical arterial (µmol L⁻¹)          | 122.1 vs 215** | 0.18 vs 0.39**          | 0.4 vs. 0.4**          | -                     | -                    |
| Khaw et al. 2009 | 125         | 0.21 vs. 0.6                     | Maternal venous (pg ml⁻¹)              | 225 vs. 240.7 | -                      | -                     | -                     | -                    |
|                 |             |                                  | Umbilical venous (pg ml⁻¹)             | 427 vs. 471 | -                      | -                     | -                     | -                    |
|                 |             |                                  | Umbilical arterial (pg ml⁻¹)           | 457 vs. 473 | -                      | -                     | -                     | -                    |
| Khaw et al. 2010 | 39          | 0.3 vs. 0.5 vs. 1.0              | Maternal arterial (pg ml⁻¹)            | 154 vs. 156 vs. 158 | -                      | -                     | -                     | -                    |
|                 |             |                                  | Umbilical venous (pg ml⁻¹)             | 480 vs. 416 vs. 441 | -                      | -                     | -                     | -                    |
|                 |             |                                  | Umbilical arterial (pg ml⁻¹)           | 410 vs. 368 vs. 468 | -                      | -                     | -                     | -                    |
| Koksal et al. 2016 | 40        | 0.4 vs. 0.8                      | Subject arterial (nmol mg⁻¹)          | -           | -                      | 8.1 vs. 8.1           | 5.8 vs. 7.5          | -                    |
|                 |             |                                  | Subject bronchial lavage (nmol mg⁻¹)   | -           | -                      | 7.7 vs. 12.6**        | 10.1 vs. 4.5**       | -                    |
| Ahuja et al. 2018 | 60         | 0.21 vs. 0.5 (EL C/S)            | Maternal arterial (µM)                | -           | -                      | 6.1 vs. 6.2           | -                     | -                    |
|                 |             |                                  | Umbilical venous (µM)                 | -           | -                      | 5.3 vs. 4.8           | -                     | -                    |
|                 |             |                                  | Umbilical arterial (µM)               | -           | -                      | 5.4 vs. 4.3           | -                     | -                    |
|                 |             |                                  | Maternal arterial (µM)                | -           | -                      | 6.1 vs. 6.2           | -                     | -                    |
| Study                        | Duration | Measurement                                    | Value | P-value |
|-----------------------------|----------|-----------------------------------------------|-------|---------|
| Oldman AH et al. 2020       | 60 (EM C/S) | Umbilical arterial (µM) | -     | 5.1 vs. 5.5 |
|                             |          | Umbilical venous (µM) | -     | 5.4 vs. 4.8 |
| Garcia de la Asuncion et al. 2007 | 30       | Subject arterial 1 hour after induction (nmol ml\(^{-1}\)) | -     | 0.6 vs. 0.5 |
|                             |          | Subject arterial 6 hours post-op (nmol ml\(^{-1}\)) | -     | 0.65 vs. 0.4* |
| Garcia de la Asuncion et al. 2013 | 24       | Subject mucosal (nmol mg\(^{-1}\) protein\(^{-1}\)) | -     | 2.0 vs. 1.0** |
|                             |          | Subject mucosal (mU mg\(^{-1}\) protein\(^{-1}\)) | -     | 595 vs. 310* |
|                             |          | Subject arterial (nmol mg\(^{-1}\) ml\(^{-1}\)) | -     | 1.5 vs. 0.4** |
### Table 2. Results of RCTs reporting on antioxidant levels in blood and bronchial lavage. *p<0.05 **p<0.01.

| Author                     | Patient no. | Control vs. Intervention (FIO₂) | Sample                        | Superoxide Dismutase, SOD (nmol mg⁻¹) | Non-protein sulphydryl, NPSH (nmol mg⁻¹) | Protein sulphydryl, PSH (nmol mg⁻¹) | Reduced Glutathione, GSH (µmol ml⁻¹) | Oxidised Glutathione, GSSG (nmol mg⁻¹ ml⁻¹) | Total Antioxidant Status, TAS (mM) |
|----------------------------|-------------|---------------------------------|-------------------------------|--------------------------------------|----------------------------------------|-------------------------------------|----------------------------------------|-------------------------------------|-------------------------------------|
| Koksal et al. 2016         | 40          | 0.4 vs. 0.8                     | Subject Arterial              | 3.6 vs. 1.4**                        | 2.56 vs. 2.7                           | 3.2 vs. 2.6*                        | -                                      | -                                   |                                     |
|                            |             |                                 | Subject Bronchial Lavage      | 13.7 vs. 13.4**                     | 2.2 vs. 1.2**                          | 11.8 vs. 6.7**                       | -                                      | -                                   |                                     |
| Garcia de la Asuncion et al. 2007 | 30          | 0.3 vs 0.8                      | Subject arterial 1 hour after induction | -                                    | -                                      | -                                   | 0.68 vs 0.58                           | 1.2 vs 0.8                         | 20 vs 30**                          |
|                            |             |                                 | Subject atrial 6 hours post-op | -                                    | -                                      | -                                   | 0.78 vs. 0.7                           | 1.2 vs 0.8                         | 42 vs 30**                          |
| Garcia de la Asuncion et al. 2013 | 24          | 0.3 vs. 0.8                     | Subject arterial              | -                                    | -                                      | -                                   | -                                      | 1.1 vs. 1.1                         |                                     |
| Ahuja et al. 2018          | 60 (EL C/S) | 0.21 vs 0.5                     | Maternal arterial             | -                                    | -                                      | -                                   | -                                      | -                                   | 1.1 vs. 1.1                         |
|                            |             |                                 | Umbilical arterial            | -                                    | -                                      | -                                   | -                                      | -                                   | 1.2 vs 1.3                         |
|                            |             |                                 | Umbilical venous              | -                                    | -                                      | -                                   | -                                      | -                                   | 1.3 vs 1.3                         |
| Ahuja et al. 2018          | 60 (EM C/S) | 0.21 vs 0.5                     | Umbilical arterial            | -                                    | -                                      | -                                   | -                                      | -                                   | 1.1 vs. 1.1                         |
|                            |             |                                 | Umbilical venous              | -                                    | -                                      | -                                   | -                                      | -                                   | 1.6 vs. 1.5                         |